目的 探討慈丹膠囊聯(lián)合厄洛替尼治療晚期非小細(xì)胞肺癌的臨床療效。方法 收集2014年3月-2016年3月在保定市第一醫(yī)院治療的晚期非小細(xì)胞肺癌患者94例，隨機(jī)分為對(duì)照組（47例）和治療組（47例）。對(duì)照組患者口服鹽酸厄洛替尼片，150 mg/次，1次/d，直到疾病進(jìn)展或出現(xiàn)不能耐受的毒性反應(yīng)。治療組患者在對(duì)照組的基礎(chǔ)上口服慈丹膠囊，1.35 g/次，4次/d。兩組均經(jīng)過2個(gè)月治療。評(píng)價(jià)兩組患者臨床療效，同時(shí)比較治療前后兩組患者腫瘤標(biāo)志物水平、血清學(xué)指標(biāo)、QLQ-C30評(píng)分、疾病進(jìn)展時(shí)間和平均生存時(shí)間。結(jié)果 治療后，對(duì)照組客觀緩解率為27.66%，臨床獲益率為74.47%，均分別低于治療組的48.94%、91.49%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組癌胚抗原（CEA）、CA153、CA242水平均顯著降低（P<0.05）；且治療組比對(duì)照組降低更顯著（P<0.05）。治療后，兩組血清血管內(nèi)皮生長因子（VEGF）、基質(zhì)金屬蛋白酶-2（MMP-2）、可溶性細(xì)胞黏附因子-1（sICAM-1）和S100鈣結(jié)合蛋白A4（S100A4）水平均明顯降低（P<0.05）；且治療組降低的更明顯（P<0.05）。治療后，兩組軀體、認(rèn)知、情緒、角色和社會(huì)功能等QLQ-C30功能領(lǐng)域評(píng)分均顯著升高（P<0.05）；且治療組比對(duì)照組升高更顯著（P<0.05）。治療后，治療組患者疾病進(jìn)展時(shí)間和平均生存時(shí)間均明顯優(yōu)于對(duì)照組患者，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 慈丹膠囊聯(lián)合厄洛替尼治療晚期非小細(xì)胞肺癌可有效降低血清腫瘤標(biāo)志物水平，延長生存時(shí)間，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical effect of Cidan Capsules combined with erlotinib in treatment of advanced non-small cell lung cancer. Methods Patients (94 cases) with advanced non-small cell lung cancer in Baoding No.1 Hospital from March 2014 to March 2016 were randomly divided into control (47 cases) and treatment (47 cases) groups. Patients in the control group were po administered with Erlotinib Hydrochloride Tablets until the disease progress or the emergence of intolerable toxicity, 150 mg/time, once daily. Patients in the treatment group were po administered with Cidan Capsules on the basis of the control group, 1.35 g/time, four times daily. Patients in two groups were treated for 2 months. After treatment, the clinical efficacy was evaluated, and the tumor markers levels, serological indexes, QLQ-C30s score, the time of disease progression and average survival in two groups before and after treatment were compared. Results After treatment, objective remission rate and disease control rate in the control group were 27.66% and 74.47%, which were significantly lower than 48.94% and 91.49% in the treatment group, respectively, and there were differences between two groups (P<0.05). After treatment, the CEA, CA153 and CA242 levels in two groups were significantly decreased (P<0.05). And these indexes levels in the treatment group were obviously lower than those in the control group (P<0.05). After treatment, the VEGF, MMP-2, sICAM-1 and S100A4 levels in two groups were significantly decreased (P<0.05). And these indexes levels in the treatment group were obviously lower than those in the control group (P<0.05). After treatment, the QLQ-C30 scores of body, cognition, emotion, role and social function in the treatment group were obviously increased (P<0.05). And these scores in the treatment group were obviously higher than that in the control group (P<0.05). After treatment, the time of disease progression and average survival in the treatment group were obviously better than that in the control group, with significant difference between two groups (P<0.05). Conclusion Cidan Capsules combined with erlotinib can effectively reduce the serum tumor markers level and prolong the survival time in treatment of advanced non-small cell lung cancer, which has a certain clinical application value.